Kornimate/medical-research-clean huggingface dataset:
comparison of lanreotide autogel® and sandostatin lar depot in the treatment of clinical symptoms associated with carcinoid syndrome

Conditions: Malignant Carcinoid Syndrome

Summary: the aim of this study is to compare the efficacy and safety of lanreotide autogel and sandostatin lar depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of a neuroendocrine tumor of the carcinoid type. * documented evidence of carcinoid syndrome (flushing and/or diarrhea) attributable to a primary tumor of the lung, stomach or mid-gut. * previous positive octreoscan. * world health organization (who) performance score lower than 2. at the baseline visit patients must satisfy the following criteria before they are randomized to receive study treatment: * stool and/or flushing frequency of greater than or equal to 3 episodes/day (average over a minimum five consecutive days). * patients who have previously been treated with somatostatin analogues must have discontinued treatment for a sufficient period of time (a washout period of at least 7 days for immediate release formulations and up to 2 months for prolonged release formulations is usually required). compared with their "controlled" state on treatment, these patients must show a clinically significant deterioration (at least two episodes) of either symptom. for example, a patient considered to be controlled on their previous treatment with an estimated stool frequency of two episodes per day, must achieve a stool frequency of at least four episodes per day (average over a minimum five consecutive days). * who performance score lower than 2. exclusion criteria: * vipoma or other non-carcinoid tumor. * treatment with interferon, chemotherapy or radiotherapy given within 30 days prior to inclusion, or planned during the study. * radionuclide treatment within three months prior to inclusion, or planned during the study. * presence of other active malignant pathology (except basal cellular carcinoma of the skin and/or in situ carcinoma of the cervix/uterus). * surgical procedure or embolization procedure (with or without cytotoxic agents) of the tumor within three months prior to inclusion, or planned during the study. * life expectancy of less than 6 months. * any investigational drug given within 30 days prior to inclusion or expected to be given during the study. * no access to a telephone for completion of the daily telephone diary.

Keywords: carcinoid syndrome neuroendocrine tumuors
footwear difference in sports use in runners with functional equinus

Conditions: Sport Injury

Summary: observational study on nimbus shoes for daily training with 8mm drop and designed for heavier than normal weight. shoe weight is 300g with highly structured buttress and upper with internal heat-sealed midfoot for greater lateral stability. this is a novablast shoe with a mixed profile for training and competition with 8mm drp and higher midfoot compression range with less lateral containment.


Eligibility criteria:
inclusion criteria: * patients with functional equine * regular runners exclusion criteria: * patients with severe heterometry (more than 1 cm). * recent lower limb interventions

Keywords: halffoot sports shoe daily training competition
an online-platform to improve patient-centered care during the covid-19 pandemic: a gimema surveillance program in hematologic malignancies

Conditions: Hematologic Malignancies

Summary: this is a national multicenter prospective observational study led by the gimema. the gimema-alliance platform is also an online monitoring system for patients with hematologic malignancies aiming at helping hematologists in the early recognition and timely management of problems of their patients. based on patient's rating of specific items (i.e. on the presence of clinically relevant problems or problems with adherence to therapy or risk of sars-cov-2 infection), the platform will automatically send alerts to the treating hematologist (and/or appointed members of the local team). physicians will be free to make any action they feel appropriate for the best care of their patients.


Eligibility criteria:
inclusion criteria: * diagnosis of any hematologic malignancy according to 2016 who classification * adult patients (≥18 years). * written informed consent exclusion criteria: * major cognitive deficits or psychiatric problems hampering a self-reported evaluation. * not able to read and understand local language
time course of neuro-ventilatory efficiency during a spontaneous breathing training

Conditions: Ventilator Weaning; Respiration, Artificial; Respiratory Muscles; Respiratory Failure; Critical Care

Summary: the tones trial aims to evaluate the neuroventilatory efficiency (nve = tidal volume / peak voltage of diaphragm contraction) measured during a zero-assist manoeuvre (zam, i.e. with peep but without pressure support). this novel parameter, nve-zam, will be studied in a blocked, crossover, repeated measures design. possible confounders, such as activity of respiratory muscles other than the diaphragm, are included. the investigators hypothesized that * the nve during a zero-assist maneuver has a low variability and high repeatability at the same level of peep (within subjects, within blocks) * nve-zam trends differ between participants (between subjects, within blocks) and between peep levels (within subjects, between blocks) the primary aim is to study the variability and repeatability of the nve-zam within subjects and within blocks. additionally, the effect of peep, muscle fatigue and recruitment of the accessory and expiratory muscles of respiration on the nve-zam will be studied in an exploratory analysis (in multiple combinations of within and between subjects and/or blocks).


Eligibility criteria:
inclusion criteria: * adult (18-80 yrs.) * admitted to the icu * intubated and mechanically ventilated * edi catheter (maquet, solna, sweden) in situ as part of their clinical care * ventilated in a support mode (e.g. pressure support) with a support between 7 and 15 cmh2o, a peep ≤10 cmh2o and an fi02 \<0.6, all since ≥6 hours. * can participate in the trial as judged by their attending physician exclusion criteria: * pregnancy * refusal of participation * pre-existing neuromuscular disorders (e.g., guillain-barré)
identification of protein markers of epidemiological and clinical interest by maldi-tof

Conditions: Infectious Risk

Summary: not all infectious agents have the same epidemic potential, and this can vary widely within the same species. rapid determination of this potential is essential to optimize control of infectious diseases. it is now accepted that identification with the species is clearly insufficient to identify an epidemic and to carry out epidemiological analyzes. indeed, if the same bacterial species can present a great diversity of strains, it is organized in clonal complexes having strong variations of clinical and epidemiological expression. more specifically, on a bio-epidemiological level, the clonal identification of the bacterial agent is a real asset because it can make it possible to identify the highly virulent strains or known to be resistant, the clones associated with nosocomial infections, the source of the infection. an epidemic and to follow its spatio-temporal extension, to know the epidemiological antiquity of the clone, to follow or rebuild a chain of transmission, to discover epidemic clusters. there are rapid identification techniques, for example by polymerase chain reaction (pcr), but which are targeted at particular genomic compositions previously identified. routine bacterial identification now rests on the determination of the protein composition by mass spectrometry (maldi-tof). the bacterial spectrum is compared to a reference library of protein composition, thus obtaining an identification equivalent to that based on the 16s rna (ribonucleic acid 16s) and can descend to an infra-species level. the aim of this work is to use the proteome part of the maldi-tof spectrum to identify peaks that signal clonality and to determine proteomic fingerprintings that can be used for epidemiological and clinical purposes. instead of relying on expensive genomic methods, the identification of the clonal characteristics of the strains will rely on the bacterial proteome present on the maldi-tof spectrum that is produced during the routine identification of the bacterium. the results are intended to feed a complementary knowledge base


Eligibility criteria:
inclusion criteria: * bacterial identification by matrix assisted laser desorption ionisation - time of flight (maldi-tof) exclusion criteria: * unidentified strain or noisy spectrum
perfusion index and pleth variability index in cesarean section.

Conditions: Cesarean Section Complications

Summary: the aim of this study is to investigate the predictability of hypotension by using pi and pvi in pre-and post-spinal anesthesia periods in cesarean section cases in the sitting position.

spinal anesthesia has been widely used all over the world due to its superiority to general anesthesia in cesarean section. however, as a result of the sympathetic blockade in spinal anesthesia, vascular tone decreases and hypotension occurs. the incidence of hypotension increases up to 70% in pregnant women due to increased sensitivity to local anesthetics and increased intraabdominal pressure. improper management of postspinal hypotension may lead to maternal and fetal complications. predicting the risk of hypotension in patients undergoing spinal anesthesia may allow applications such as volume loading or prophylactic vasopressor use. the perfusion index, measured by pulse oximeters, correlates with blood flow changes at the tip of the finger so that it can detect hypotension and thus decrease in blood flow after spinal anesthesia. pleth variability index (pvi) is a non-invasive value found in the new generation pulse oximeters. it is a parameter used in the dynamic measurement of response to fluid therapy in intensive care units. pvi can dynamically give an idea about the fluid status of the pregnant woman. previous studies have shown that pvi may be a marker for predicting hypotension following spinal anesthesia.

Eligibility criteria:
inclusion criteria: * pregnant women who will undergo elective cesarean section exclusion criteria: * preeclampsia * cardiovascular disorder * fetal abnormality * patients who failed spinal anesthesia or switched to general anesthesia during operation.

Keywords: cesarean section perfusion index pleth variability index sitting position
home-based transcranial electrical stimulation (tes) in patients with chronic tinnitus

Conditions: Tinnitus; Depression; Depressive Disorder; Hearing Disorders; Otorhinolaryngologic Diseases

Summary: the investigators applied home-based transcranial electrical stimulation (tes) for neuromodulative treatment in patients with intractable chronic tinnitus.

for treatment of motor and psychiatric disorders, transcranial electrical stimulation including transcranial direct current stimulation (tdcs), transcranial magnetic stimulation (tms), or transcranial random noise stimulation (trns) are in use worldwidely. the investigators applied these neuromodulation techniques into patients with intractable chronic tinnitus for symptom relief. experimental groups with 60 subjective tinnitus subjects will be consisted of three different treatment groups which are: tes group, tes with sham stimulation group, and control group. subjects will be given 1.0 milliampere (ma) tes on bifrontal areas for neuromodulation.

Eligibility criteria:
inclusion criteria: * research volunteers with intractable chronic tinnitus who agreed to participate in the clinical trial were gathered from the tinnitus clinic of the department of otorhinolaryngology head-and-neck surgery, seoul national university bundang hospital exclusion criteria: * psychoactive drug user * implanted material * pacemaker user

Keywords: transcranial electrical stimulation tinnitus
expanded access program for olaparib tablets as maintenance therapy in patients with ovarian, fallopian tube or primary peritoneal cancer.

Conditions: Ovarian Cancer

Summary: this is an open-label, single-arm, international, multicenter multiple patient expanded access program (mpeap). the program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer without other treatment options or eligible for an olaparib clinical trials.

the multiple patient expanded access program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) following platinum-based chemotherapy. the dose of olaparib tablets is 300 mg (two 150 mg tablets) taken twice daily, equivalent to a total daily dose of 600 mg. the 100 mg tablet is available for dose reduction. treatment may continue until disease progression, unacceptable toxicity or withdrawal of patient consent. the program will collect observational data only.

Eligibility criteria:
inclusion criteria for inclusion in the program patients must fulfill the following criteria: * provision of informed consent prior to any program specific procedures * female patients ≥ 18 years of age and has platinum-sensitive relapsed high grade epithelial ovarian, primary peritoneal or fallopian tube cancer * patient is in response (complete response or partial response) following platinum-based chemotherapy. * patients must have normal organ and bone marrow function measured within 28 days prior to administration of program treatment. * postmenopausal or evidence of non-childbearing status for women of childbearing potential. exclusion criteria: patients should not enter the program if any of the following exclusion criteria are fulfilled: * patients with a known hypersensitivity to olaparib or any of the excipients of the product. * concomitant use of known strong cyp3a inhibitors or moderate cyp3a inhibitors. * concomitant use of known strong or moderate cyp3a inducers. the required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents. * patient with moderate or severe hepatic impairment. * breast feeding women.

Keywords: ovarian cancer gynaecological cancer platinum-sensitive disease platinum-sensitive relapsed olaparib ovarian neoplasms neoplasms ovarian disease fallopean tube cancer primary peritoneal cancer epithelial ovarian cancer parp inhibitors poly (adp-ribose) polymerase inhibitors.
a comparative study of gpi's dbs and pallidotomy in the treatment of meige syndrome

Conditions: Meige Syndrome; Meigs Syndrome; Meige Disease; Meig Syndrome; Blepharospasm; Blepharospasm of Left Eyelid; Blepharospasm of Right Eyelid; Blepharospasm of Both Eyelids; Blepharospasm Oromandibular Dystonia

Summary: in this study, we will compare the degree of postoperative symptom improvement, postoperative complication rate, postoperative quality of life improvement degree of patients with meige syndrome undergoing pallidotomy (unilateral globus palliotomy) and deep brain stimulation (unilateral globus pallidus) ,in order to get the conclusion of the comparison of the clinical efficacy of the two surgical plans. in addition, possible predictive factors such as age, gender, age of onset, length of disease course, scale baseline score, preoperative brain pet-ct function analysis and other possible predictive factors are added for analysis, in order to find predictive factors that can guide the choice of surgical options.


Eligibility criteria:
inclusion criteria: * patients confirmed meige sydrome exclusion criteria: * patients who cannot finish the neurosurgery or the postoperative evaluation

Keywords: deep brain stimulation dbs dbnl gpi pallidotomy
preanalgesic effect of gabapentin in total knee repair

Conditions: Pain

Summary: the purpose of this study is to determine whether gabapentin, as a one time administration prior to a total knee replacement procedure, has opioid sparing effects and a reduction in pain scores.


Eligibility criteria:
inclusion criteria: * patients undergoing total knee replacement who received pain management by the following modality: * intravenous patient-controlled analgesia (iv-pca) opioid * local femoral nerve block with 1.5% mepivacaine 20 ml and 0.5% ropivacaine 20 ml exclusion criteria: * age \< 18 years old

Keywords: patients undergoing total knee replacement who received pain management by the following modality: iv pca opioid local femoral nerve block with 1.5% mepivacaine & 0.5% ropivacaine
neopterin in acute coronary syndrome patients

Conditions: Neopterin in Acute Coronary Syndrome Patients

Summary: measurement of neopterin in acs patients

1. detect level of neopterin in acs patients to detect whether there is relation or not between acs and neopterin 2. detection of relation between neopterin and cardiac enzymes as ck and troponine in acs patients 3. detect relation between neopterin level and in hospital events

Eligibility criteria:
inclusion criteria: * all patient of sample size admitted to cardiology departmentof assiut university hospital with : 1. acute typical chest pain 2. positive cardiac enzymes 3. ecg show recent ischemic changes 4. echo show swma exclusion criteria: 1. patients not fulfill inclusion criteria. 2. patients with other diseases which may cause increase of neopterin level as viral infections, intracellular bacteria or parasites infections, certain malignancies, allograft rejection
controlled study of humira in subjects with chronic plaque psoriasis of the hands and/or feet

Conditions: Psoriasis

Summary: evaluate the efficacy and safety of a 16-week course of humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.


Eligibility criteria:
inclusion criteria: * adult with diagnosis of chronic plaque psoriasis of the hands and feet for at least 6 months, with a pga \>/=3 and candidates for systemic therapy; * patients in good general health * able to self-administer injections * negative chest x-ray (cxr) and purified protein derivative (ppd) test, unless willing to start anti-tuberculosis (tb) prophylaxis exclusion criteria: * previous treatment with humira® * required mediation stability or washouts for: systemic corticosteroids (28 days), other investigational agent, other systemic therapies for psoriasis, ultraviolet b (uvb), psoralen with uva (puva) * other active skin diseases or skin infections * diagnosis of palmoplantar pustulosis; erythrodermic psoriasis, pustular psoriasis, medication-induced or exacerbated psoriasis or new onset of guttate psoriasis * evidence of dysplasia or history of malignancy (other than a successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix); * history of listeriosis, histoplasmosis, chronic or active hepatitis b infection, human immunodeficiency virus (hiv) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (tb); * history of moderate to severe congestive heart failure, * recent cerebrovascular accident and any other condition which, in the opinion of the investigator, would put the subject at risk; * history of central nervous system (cns) demyelinating disease or neurologic symptoms suggestive of cns demyelinating disease; * history of clinically significant drug or alcohol abuse in the last 12 months; * infection(s) requiring treatment with intravenous (iv) antibiotics, iv antivirals, or iv antifungals within 30 days prior to baseline or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to baseline; * known hypersensitivity to the excipients of humira® as stated in the label; * female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study. * prior exposure to tysabri® (natalizumab)
grafting of epidermolysis bullosa wounds using cultured revertant autologous keratinocytes

Conditions: Epidermolysis Bullosa

Summary: the term epidermolysis bullosa (eb) is used to describe a group of genetic skin diseases associated with skin weakness, blisters, and chronic wounds. "revertant mosaicism" means that there are two genetically different populations of cells due to spontaneous mutations. some eb patients have normal, non-fragile skin patches which may be areas of revertant mosaicism. in the revertant areas, the proteins function normally, like non-eb skin. in this study, we plan to culture cells from the revertant areas and graft them on to the wounded areas.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of eb (simplex, junctional or dystrophic) * areas of revertant skin that has been confirmed by biopsy * 18 years or older subject willing and able to give consent * confirmation of eb diagnosis by immunofluorescence (if), electron microscopy (em), and genetic testing confirming mutation * at least 100 to 200 cm2 of open erosions on the trunk and/or extremities suitable for skin grafting * able to undergo adequate anesthesia to allow grafting procedures to take place exclusion criteria: * medical instability limiting ability to travel to stanford university medical center * the presence of medical illness expected to complicate participation and/or compromise the safety of this technique * active infection with hiv, hepatitis b, or hepatitis c * active infection in the area that will undergo grafting * evidence of a systemic infection * current evidence or a history of skin cancer in the area that will undergo grafting * active drug or alcohol addiction * hypersensitivity to vancomycin or amikacin * receipt of chemical or biological study product for the specific treatment ofeb in the past six months * positive pregnancy test or breast-feeding